Study of the effects of preparation containing ultralow doses of antibodies to S-100 protein in experimental hemorrhagic stroke.
Ultralow doses of antibodies to S-100 protein increased rat survival, reduced neurological deficit, eliminated myorelaxation, and improved movement coordination and cognitive functions in rats with experimental hemorrhagic stroke; the efficiency of the preparation was not inferior to that of nimodipine. In contrast to nimodipine, ultralow doses of antibodies to S-100 protein exhibited pronounced anxiolytic properties.
Voronina
T A
TA
Materia Medica Holding Research-and-Production Company, Moscow.
Kheyfets
I A
IA
Dugina
Yu L
YL
Sergeeva
S A
SA
Epshtein
O I
OI
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000627:therapeutic use*; D020300:Intracranial Hemorrhages / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D009553:Nimodipine / Q000627:therapeutic use; D051381:Rats; D009418:S100 Proteins / Q000276:immunology*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000906:Antibodies; D009418:S100 Proteins; D014665:Vasodilator Agents; D009553:Nimodipine